adminVertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Q4 2024 Earnings Conference Call February 10, 2025 4:30 PM ET
Company Participants
Susie Lisa – Senior Vice President, Investor Relations
Reshma Kewalramani – President and Chief Executive Office
Stuart Arbuckle – Chief Operating Officer
Charlie Wagner – Chief Financial Officer
Conference Call Participants
Salveen Richter – Goldman Sachs
Evan Seigerman – BMO Capital Markets
Jessica Fye – JPMorgan
Geoff Meacham – Citibank
Michael Yee – Jefferies
William Pickering – Bernstein
Liisa Bayko – Evercore ISI
Phil Nadeau – TD Cowen
Eliana Merle – UBS
Tazeen Ahmad – Bank of America
Dave Risinger – Leerink Partners
Olivia Brayer – Cantor Fitzgerald
Operator
Good day, and welcome to the Vertex Pharmaceuticals Fourth Quarter 2024 Earnings Call. All participants will be in a listen-only mode. [Operator Instructions] After today’s presentation, there will be an opportunity to ask questions. [Operator Instructions] Please note this event is being recorded.
I would now like to turn the conference over to Ms. Susie Lisa. Please go ahead, ma’am.
Susie Lisa
Good evening, all. My name is Susie Lisa. And as the Senior Vice President of Investor Relations, it is my pleasure to welcome you to our fourth quarter 2024 financial results conference call.
On tonight’s call, making prepared remarks, we have Dr. Reshma Kewalramani, Vertex’s CEO and President; Stuart Arbuckle, Chief Operating Officer; and Charlie Wagner, Chief Financial Officer. We recommend that you access the webcast slides as you listen to this call. The call is being recorded, and a replay will be available on our website.
We will make forward-looking statements on this call that are subject to the risks and uncertainties discussed in detail in today’s press release and in our filings with the Securities and Exchange Commission. These statements, including, without limitation, those regarding Vertex’s marketed medicines for cystic fibrosis, sickle cell disease, beta thalassemia
Read the full article here
